Voyager Therapeutics Financials
| VYGR Stock | USD 5.75 0.06 1.05% |
Operating Margin (0.56) | PE Ratio 8.7121 | Profit Margin 0.158 | Short Ratio 4.44 | EPS Estimate Current Year (0.91) |
Voyager |
Voyager Therapeutics Stock Summary
Voyager Therapeutics competes with Fate Therapeutics, Sana Biotechnology, Caribou Biosciences, Arcus Biosciences, and Karyopharm Therapeutics. Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Voyager Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US92915B1061 |
| CUSIP | 92915B106 |
| Location | Massachusetts; U.S.A |
| Business Address | 75 Hayden Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.voyagertherapeutics.com |
| Phone | 857 259 5340 |
| Currency | USD - US Dollar |
Voyager Therapeutics Key Financial Ratios
Voyager Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Voyager Therapeutics's current stock value. Our valuation model uses many indicators to compare Voyager Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Voyager Therapeutics competition to find correlations between indicators driving Voyager Therapeutics's intrinsic value. More Info.Voyager Therapeutics is rated second in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.15 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Voyager Therapeutics is roughly 6.51 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Voyager Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Voyager Therapeutics Systematic Risk
Voyager Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Voyager Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Voyager Therapeutics correlated with the market. If Beta is less than 0 Voyager Therapeutics generally moves in the opposite direction as compared to the market. If Voyager Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Voyager Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Voyager Therapeutics is generally in the same direction as the market. If Beta > 1 Voyager Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Voyager Therapeutics Thematic Clasifications
Voyager Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Voyager Therapeutics December 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Voyager Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Voyager Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Voyager Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Voyager Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Voyager Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.23 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 36.72 | |||
| Value At Risk | (7.03) | |||
| Potential Upside | 9.47 |
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.